MAZE THERAPEUTICS, INC. Total Liabilities and Equity
MAZE THERAPEUTICS, INC. (MAZE) had Total Liabilities and Equity of $531.63 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-11
- 2026-06-30: Liabilities and Equity $531.63M.
- 2026-03-31: Liabilities and Equity $419.71M.
- 2025-12-31: Liabilities and Equity $397.13M.
- 2025-09-30: Liabilities and Equity $422.06M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $531.63M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $419.71M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $397.13M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $422.06M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $303.52M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $332.84M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $240.54M 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |